MOBOCERTINIB (has an active metabolite) 
| MOBOCERTINIB | ANTINEOPLASTIC KINASE INHIBITOR TREATMENT OF NSCLC WITH EGFR EXON 20 INSERTION MUTATIONS INHIBITS KINASES HER2, HER4 AND BLK WITH IC50 BELOW 2 NANOMOLAR | ORAL | Tmax 4 HOUR F 37 PERCENT VD 3509 LITER PPB 99.3 PERCENT Cl 138 LITER / HOUR HT 18 HOUR SOLUBILITY 17 MILLIGRAM PER MILLILITER AT PH 6.8 | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) (MUTATED) HER2 HER4 BLK | More at DrugCentral | ANSM (in French) Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |